Scancell Holdings Plc Scancell to attend upcoming conferences

RNS Number : 5440Q

Scancell Holdings Plc

31 May 2024

 

31 May 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell Announces its Attendance at Upcoming Conferences

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today confirms that it will attend and present at the upcoming conferences listed below. Presentations at these high-profile conferences follow the significant recent progress that Scancell has made in developing its pipeline of innovative immunotherapies to address unmet needs in cancer.

 

·      BIO International Convention, taking place in San Diego, CA from 3-6 June.

Mandeep Sehmi, Head of Business Development, will be attending the conference.

 

·      Antibody Engineering & Therapeutics Europe, taking place in London, UK from 4-6 June.

Bubacarr Gibril Kaira, Antibody Research Scientist at Scancell, will be presenting at the conference.

Mireille Vankemmelbeke, Principal Scientist at Scancell, will also be attending.

Session Title: Fc Engineering and Fc Receptor Function

Title: Unlocking the Unique Potential of AvidiMAb® in Clustering and Signalling

Date and Time: Tuesday 4^th June at 5:15pm BST

 

If you would like to arrange a meeting with management, please contact [e-mail].

 

-ENDS-

 

For further information, please contact:
Scancell Holdings plc	[phone]
Dr Jean-Michel Cosséry, Non-Executive Chairman
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)	[phone]
Nicholas Moore/Samira Essebiyea/Ben Good
Nick Harland (Corporate Broking)
WG Partners LLP (Joint Broker) David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby	[phone]
Panmure Gordon (UK) Limited (Joint Broker)	[phone]
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
ICR Consilium	[phone]
Mary-Jane Elliott/Angela Gray/Lindsey Neville	[e-mail]

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody® ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab® ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab® ).

 

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCQKKBPABKDCPN